

(PS2131) ANTI-PD-1-ANTIBODY (TISLELIZUMAB) PLUS CHIDAMIDE, LENALIDOMIDE AND ETOPOSIDE FOR REFRACTORY/RELAPSED EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE : A PROSPECTIVE, MULTICENTER, SINGLE-ARM TRIAL

Topic: 20. Other aggressive lymphomas

Yu Chang^{*1}, Ling Li¹, Xin Li¹, Xinhua Wang¹, Xiaorui Fu¹, Zhenchang Sun¹, Xudong Zhang¹, Linan Zhu¹, Songtao Niu¹, Feifei Nan¹, Shuli Guo², Qiuli Meng³, Wei Sang⁴, Lei Zhang¹, Mingzhi Zhang¹

¹First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; ²Luoyang Central Hospital, Luoyang, China; ³Gongyi City People's Hospital, Gongyi, China; ⁴The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China;

Background

Extranodal Natural Killer/T-Cell Lymphoma (ENKTL) is a highly aggressive subtype of non-Hodgkin lymphoma with a markedly higher incidence in Asia. Patients with Refractory/Relapsed-ENKTL(r/r-ENKTL) face a dismal prognosis and have limited therapeutic options.

Aims

To evaluate the efficacy and safety of a novel regimen comprising Tislelizumab, Chidamide, Lenalidomide and Etoposide in patients with r/r-ENKTL.

Methods

This was a prospective, single-arm, open-label, multicenter clinical trial enrolling adult patients with r/r-ENKTL who had received at least one prior systemic therapy. Patients received 6 cycles of combination therapy comprising Tislelizumab (200mg, Day 1), Chidamide (20mg, biw), Lenalidomide (25mg, Days 1-10) and Etoposide (100mg/m², Days 1-3) every 21 days, followed by 10 cycles of Tislelizumab maintenance (200mg, Day1) every 21 days. The primary endpoints were objective response rate (ORR) and progression-free survival (PFS). This trial is registered at ClinicalTrials.gov (NCT04038411).

Copyright Information: (Online) ISSN: 2572-9241

©2026 The Author(s). HemaSphere is published by John Wiley & Sons Ltd on behalf of European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. **Abstract Book Citations:** Authors, Title, HemaSphere, 2026;10;(S1):pages. The abstract book DOIs can be found on the "Author Information" page.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.

Results

From June 2020 to December 2025, 38 eligible patients with r/r-ENKTL were enrolled from 5 centers. The final follow-up occurred on February 20, 2026, with a median follow-up of 32 months (range: 2-67 months). The median age of the cohort was 39 years (range, 17-63 years). All patients received at least four cycles of induction chemotherapy. Among the 38 efficacy-evaluable patients, the overall response rate (ORR) was 84.2% (32/38), including a complete response (CR) rate of 60.5% (23/38). During Tislelizumab maintenance therapy, an additional one patients achieved CR, resulting in a cumulative CR rate of 65.8% (25/38) at the end of maintenance treatment. The median progression-free survival (PFS) was 49.0 months (95%CI: 24.3-3.7). Estimated PFS rates at 1, 2, and 5 years were 72.7%, 55.5%, and 42.3%, respectively. Median overall survival (OS) was not reached; corresponding 1-year, 2-year, and 5-year OS rates were 81.1%, 69.9%, and 54.9%. At last follow-up, 17 patients remained in continuous CR. The most common treatment-related adverse events (TRAEs) were anemia (83.3%), leukopenia (80.0%), neutropenia (80.8%), and thrombocytopenia (56.7%). The most frequent grade ≥3 TRAE was neutropenia (46.7%). Immune-related adverse events of grade 3 or higher included one case each of hypothyroidism and hyperglycemia.

Characteristic	Total (%)
Sex (male)	27(71.1)
B symptoms (Yes)	14(36.8)
CA Stage(III-IV)	36(94.7)
PINK score	
0-2	27(71.1)
3-4	11(28.9)
Prior PD-1 mAb use	3(7.9)

Summary/Conclusion

This regimen demonstrated promising efficacy and a favorable safety profile in patients with r/r-ENKTL.

Copyright Information: (Online) ISSN: 2572-9241
©2026 The Author(s). HemaSphere is published by John Wiley & Sons Ltd on behalf of European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
Abstract Book Citations: Authors, Title, HemaSphere, 2026;10;(S1):pages. The abstract book DOIs can be found on the “Author Information” page.
Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.